Plasma NT-proBNP as a more reliable biomarker of endogenous cardiac natriuretic peptides than BNP during carperitide infusion

International Heart Journal

Volumn 50, Issue 2, 2009, Pages 183-190

  Nishiyama, Keizo ^a   Tsutamoto, Takayoshi ^a   Tanaka, Toshinari ^a   Fujii, Masanori ^a   Yamamoto, Takashi ^a   Yamaji, Masayuki ^a   Horie, Minoru ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Atrial natriuretic peptide; Brain natriuretic peptide; Carperitide; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NPPA PROTEIN, HUMAN; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELIABILITY; ALGORITHM; BLOOD; CHRONIC DISEASE; DIFFERENTIAL DIAGNOSIS; HEART FAILURE; HOSPITALIZATION; INFUSION PUMP; MIDDLE AGED; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ALGORITHMS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CHRONIC DISEASE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEART FAILURE; HUMANS; INFUSION PUMPS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67449085986     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.183     Document Type: Article

References (26)

1. Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation 1987; 76: 115-24.
2. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4: 37-44.
3. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-6.
4. Ishikawa C, Tsutamoto T, Wada A, et al. Inhibition of aldosterone and endothelin-1 by carperitide was attenuated with more than 1 week of infusion in patients with congestive heart failure. J Cardiovasc Pharmacol 2005; 46: 513-8.
5. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
6. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780-6.
7. Tsutamoto T, Sakai H, Nishiyama K, et al. Direct comparison of transcardiac increase in brain natriu retic peptide (BNP) and N-terminal proBNP and prognosis in patients with chronic heart failure. Circ J 2007; 71: 1873-8.
8. Nohria A, Tsang SW, Fang JC, et al. Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 2003; 41: 1797-804.
9. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005; 294: 1625-33.
10. Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA 2005; 294: 1664-70.
11. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416.
12. Tsutamoto T, Kinoshita M, Nakae I, et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J 1994; 127: 866-73.
13. Haug C, Metzele A, Kochs M, Hombach V, Grünert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol 1993; 16: 553-7.
14. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-32.
15. Parsonage WA, Galbraith AJ, Koerbin GL, Potter JM. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2005; 95: 883-5.
16. Larsen AI, Dickstein K, Ahmadi NS, Aarsland T, Kvaløy JT, Hall C. The effect of altering haemodynamics on the plasma concentrations of natriuretic peptides in heart failure. Eur J Heart Fail 2006; 8: 628-33.
17. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992; 130: 229-39.
18. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.
19. Harmoinen A, Lehtimäki T, Korpela M, Turjanmaa V, Saha H. Diagnostic accuracies of plasma creatinine, cystatin C, and glomerular filtration rate calculated by the Cockcroft-Gault and Levey (MDRD) formulas. Clin Chem 2003; 49: 1223-5.
20. Tsutamoto T, Sakai H, Ishikawa C, et al. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal proBNP in patients with chronic heart failure. Eur J Heart Fail 2007; 9: 667-73.
21. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-9.
22. Luchner A, Hengstenberg C, Löwel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal proBNP. Hypertension 2005; 46: 118-23.
23. Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006; 47: 582-6.
24. Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 2005; 45: 1667-71.
25. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610-20.
26. Bruins S, Fokkema MR, Römer JW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004; 50: 2052-8.